Regeneron Pharmaceuticals Inc. (REGN)
REGN · Health Care · 
United States
Regeneron Pharmaceuticals Inc. (REGN) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 1.26%. Anyone who holds an ETF containing Regeneron Pharmaceuticals also has an indirect stake in the company.
Data and Charts: Regeneron Pharmaceuticals
Key Data for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Price Chart
The Regeneron Pharmaceuticals chart shows daily closing prices and is set to the current year by default. The stock is up 20.2% year to date and up 41.9% over twelve months. The last recorded close on October 30, 2026, was $927.89, at 100% of the 52-week range.
Price series from our database since Aug 12, 2024, 558 daily values.
Regeneron Pharmaceuticals Stock Performance
| Year to date | +20.2% | 1 year | +41.9% |
|---|---|---|---|
| 1 month | +22.4% | 3 months | +21.7% |
| Calendar year 2025 | +8.4% |
Measured in euros, Regeneron Pharmaceuticals is up 26.4% year to date and up 46.7% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Regeneron Pharmaceuticals
What ETF Is Regeneron Pharmaceuticals In?
Regeneron Pharmaceuticals has very high ETF coverage and is held by 24 of the 104 ETFs we track, which together follow 11 indices. That puts the stock in more ETFs than 90.2% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 1.26% | €12.57 |
| SPFS | MSCI World Health Care | 0.94% | €9.37 |
| XDWH | MSCI World Health Care | 0.93% | €9.30 |
| EXXT | Nasdaq 100 | 0.36% | €3.60 |
| XNAS / XNA1 | Nasdaq 100 | 0.36% | €3.59 |
| XDEW | S&P 500 Equal Weight | 0.20% | €1.97 |
| XDEB | MSCI World Minimum Volatility | 0.13% | €1.29 |
| XD9U / XD9D | MSCI USA | 0.13% | €1.26 |
| SPYL / SPY5 | S&P 500 | 0.12% | €1.20 |
| SXR8 | S&P 500 | 0.12% | €1.20 |
| SWWD | MSCI World | 0.10% | €0.96 |
| SPPW | MSCI World | 0.10% | €0.96 |
| XDWD / XDWL | MSCI World | 0.09% | €0.93 |
| SPYI / SPSA | MSCI ACWI IMI | 0.09% | €0.92 |
| EUNL | MSCI World | 0.09% | €0.90 |
| SPYY | MSCI ACWI | 0.08% | €0.83 |
| WIMI | MSCI World IMI | 0.08% | €0.83 |
| IUSQ | MSCI ACWI | 0.08% | €0.80 |
The last column shows how much of €1,000 in one of these funds goes to Regeneron Pharmaceuticals, based on each fund's latest holdings list.
US-listed ETFs holding Regeneron Pharmaceuticals (weight per latest SEC filing): QQQM 0.36%, QQQ 0.28%, ONEQ 0.18%, IVV 0.10%, SPY 0.10%, VOO 0.10%, VTI 0.09%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Regeneron Pharmaceuticals Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Regeneron Pharmaceuticals had a weight of 0.05% on Sep 30, 2019 and 0.09% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.17% on Jun 28, 2024. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Regeneron Pharmaceuticals overlaps with the rest of a portfolio.
Which Tracked Investors Hold Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds Regeneron Pharmaceuticals increased its position.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 51,333 | $32M | increased by 28,609 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
What Regeneron Pharmaceuticals Executives and Directors Traded Recently
| Date | Person | Type | Shares | Price |
|---|---|---|---|---|
| Oct 14, 2026 | MURPHY ANDREW J Officer, Co-Chief Scientific Officer | Sell (plan) | 50 | $781.47 |
| Oct 14, 2026 | MURPHY ANDREW J Officer, Co-Chief Scientific Officer | Sell (plan) | 463 | $780.63 |
| Oct 14, 2026 | MURPHY ANDREW J Officer, Co-Chief Scientific Officer | Sell (plan) | 380 | $779.59 |
| Oct 14, 2026 | MURPHY ANDREW J Officer, Co-Chief Scientific Officer | Sell (plan) | 454 | $778.64 |
| Oct 14, 2026 | MURPHY ANDREW J Officer, Co-Chief Scientific Officer | Sell (plan) | 38 | $777.76 |
| Oct 14, 2026 | MURPHY ANDREW J Officer, Co-Chief Scientific Officer | Sell (plan) | 66 | $776.31 |
| Oct 14, 2026 | MURPHY ANDREW J Officer, Co-Chief Scientific Officer | Sell (plan) | 376 | $775.46 |
| Oct 14, 2026 | MURPHY ANDREW J Officer, Co-Chief Scientific Officer | Sell (plan) | 121 | $774.48 |
The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded.
“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32.
Stocks With ETF Exposure Similar to Regeneron Pharmaceuticals
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | – | – | +41.9% | 36.5% | 31.4% | +1.0% |
 Intuitive Surgical | 23 | – | -18.5% | 34.2% | 28.4% | +20.5% |
 Amgen | 24 | – | +59.6% | 27.7% | 21.0% | +10.0% |
 Vertex Pharmaceuticals Incorporated | 24 | +0.57 | +33.1% | 31.8% | 32.9% | +8.9% |
 DexCom | 23 | – | +20.7% | 40.8% | 17.9% | +15.6% |
 Gilead Sciences | 24 | +0.48 | +44.1% | 26.8% | 28.9% | +2.4% |
 IDEXX Laboratories | 23 | – | -12.3% | 36.6% | 24.6% | +10.4% |
 GE Healthcare Technologies | 23 | – | +2.1% | 34.1% | 10.1% | +4.8% |
 McKesson Corporation | 21 | – | +20.5% | 28.4% | 1.2% | +12.4% |
These stocks reach a portfolio through largely the same funds as Regeneron Pharmaceuticals. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 13.1 | 4.0 | 30.1% |
| FY ended Dec 2024 | 14.2 | 4.4 | 31.1% |
| FY ended Dec 2025 | 14.3 | 4.5 | 31.4% |
Technical Analysis: Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Risk Metrics
The close on Oct 30, 2026, was 22.8% below the highest close since Aug 12, 2024. That high was reached on Aug 27, 2024. When the S&P 500 rose or fell 1%, Regeneron Pharmaceuticals moved 0.31% on average in the same direction (past 252 trading days). The correlation of 0.12, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Regeneron Pharmaceuticals.
What Regeneron Pharmaceuticals Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | +0.57 | |
| Pfizer Inc. | +0.54 | |
| Astrazeneca plc | +0.53 | |
| Royalty Pharma Plc Class A | +0.50 | |
| Bristol-Myers Squibb Company | +0.49 | |
| Gilead Sciences Inc. | +0.48 | |
| TFI International Inc. | -0.43 | |
| AES Corporation | -0.41 | |
| Trane Technologies plc | -0.40 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
